Literature DB >> 16278501

Racial disparities in prescription drug use for mental illness among population in US.

Euna Han1, Gordon G Liu.   

Abstract

BACKGROUND: Racial minorities are a rapidly growing portion of the US population. Research suggests that racial minorities are more vulnerable to mental illness due to risk factors, such as higher rates of poverty. Given that the burden of mental illnesses is significant, equal likelihood of mental health services utilization is important to reduce such burden. Racial minorities have been known to use mental health services less than Whites. However, it is unclear whether racial disparity in prescription drug use for mental illnesses exists in a nationally representative sample. For a valid estimation of prescription drug use patterns, the characteristic in the distribution of prescription drug use should be accounted for in the estimation model. AIMS OF THE STUDY: This study is intended to document whether there was a disparity in psychiatric drug use in both extensive and intensive margins between Whites and three racial minorities: Blacks, Hispanics, and Asian-Indians. The study looked at several specified mental illnesses, controlling for underlying health status and other confounding factors.
METHODS: Secondary data analysis was conducted using the multiyear Medical Expenditure Panel Survey (MEPS), a nationally representative panel sample from 1996 through 2000. This analysis provides estimates of the actual expenditure on prescription drug use for people with specified mental illnesses for this study, based on comparison of Whites and other racial minorities. We derived the estimates from the two-part model, a framework that adjusts the likelihood of using prescription drugs for the specified mental illnesses while estimating the total actual expenditures on prescription drugs among the users.
RESULTS: This study found that Blacks, Hispanics, and Asian-Indians were less likely than Whites to use prescription drugs by 8.3, 6.1 and 23.6 percentage points, respectively, holding other factors constant in the sample, with at least one of the specified mental illnesses. The expenditure on prescription drugs for the specified mental illnesses differs between each of racial minorities (Blacks, Hispanics, and Asian-Indians) and Whites even after adjusting for the different likelihood of using those prescription drugs. Blacks, Hispanics, and Asian-Indians with the specified mental illnesses were estimated to spend 606.53 US dollars, 9.83 US dollars and 179.60 US dollars less per year, respectively, on their actual prescription drugs than Whites. DISCUSSION: This study concludes that three racial minorities: Blacks, Hispanics, and Asian-Indians, with the specified mental illnesses are less likely to use psychiatric drugs than Whites. Among users, racial minorities use less psychiatric drugs than Whites in terms of actual spending on those drugs. IMPLICATIONS FOR HEALTH CARE PROVISION AND USE: There is a need to focus on a program to reach out to racial minorities with a diagnosis of mental illnesses, and this program should consider the cultural specificity of each minority group regarding mental illnesses. IMPLICATIONS FOR HEALTH POLICIES: In the development of mental health policy, it is crucial to understand the underlying non-socioeconomic factors which may significantly determine the access to mental health service. Also, education programs or other outreach programs for racial minorities are necessary to understand the different distribution of mental health services for racial minorities. IMPLICATIONS FOR FURTHER RESEARCH: Future research should examine the causes for racial disparity in the use of prescription drugs for mental illness both in the extensive and intensive margins. An in-depth analysis is needed to map out the attributes for the observed disparity between Whites and racial minorities in mental health service use.

Entities:  

Mesh:

Year:  2005        PMID: 16278501

Source DB:  PubMed          Journal:  J Ment Health Policy Econ        ISSN: 1099-176X


  28 in total

1.  Pharmacological treatment of Alzheimer's disease: effect of race and demographic variables.

Authors:  Santiago Hernandez; McKee J McClendon; Xiao-Hua Andrew Zhou; Michael Sachs; Alan J Lerner
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

2.  Health service utilization by Ethiopian immigrants and refugees in Toronto.

Authors:  Haile Fenta; Ilene Hyman; Samuel Noh
Journal:  J Immigr Minor Health       Date:  2007-10

3.  Estimating the effects of immigration status on mental health care utilizations in the United States.

Authors:  Jie Chen; Arturo Vargas-Bustamante
Journal:  J Immigr Minor Health       Date:  2011-08

4.  Are there racial disparities in psychotropic drug use and expenditures in a nationally representative sample of men in the United States? Evidence from the Medical Expenditure Panel Survey.

Authors:  Geraldine Pierre; Roland J Thorpe; Gniesha Y Dinwiddie; Darrell J Gaskin
Journal:  Am J Mens Health       Date:  2013-07-24

5.  Racial and ethnic disparities in pediatric mental health.

Authors:  Margarita Alegria; Melissa Vallas; Andres J Pumariega
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2010-10

6.  Race-Ethnicity and Prescription Drug Misuse: Does Self-esteem Matter?

Authors:  Clifford L Broman; Paula K Miller; Emmanuel Jackson
Journal:  J Child Adolesc Behav       Date:  2015-09-03

7.  Impact of Medicare Part D on Racial and Ethnic Minorities.

Authors:  JoEllen Jarrett Jamison; Junling Wang; Satya Surbhi; Samantha Adams; David Solomon; Kenneth C Hohmeier; Sharon McDonough; James C Eoff
Journal:  Divers Equal Health Care       Date:  2016-08-23

8.  A prospective investigation of suicide ideation, attempts, and use of mental health service among adolescents in substance abuse treatment.

Authors:  Rajeev Ramchand; Beth Ann Griffin; Katherine M Harris; Daniel F McCaffrey; Andrew R Morral
Journal:  Psychol Addict Behav       Date:  2008-12

9.  Racial and ethnic disparities in the treatment of a Medicaid population with schizophrenia.

Authors:  Marcela Horvitz-Lennon; Thomas G McGuire; Margarita Alegria; Richard G Frank
Journal:  Health Serv Res       Date:  2009-09-24       Impact factor: 3.402

10.  Memantine and acetylcholinesterase inhibitor treatment in cases of CDR 0.5 or questionable impairment.

Authors:  McKee J McClendon; Santiago Hernandez; Kathleen A Smyth; Alan J Lerner
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.